Drugs / IBI3002
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07015762 | Jul 2025 → May 2026 overdue | atopic eczema | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1 | NCT07015749 | Jun 2025 → May 2026 overdue | asthma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1 | NCT06947408 | May 2025 → May 2026 | asthma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06213844 | Feb 2024 → Jul 2025 | asthma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07399067 | Feb 2026 → Mar 2027 expected | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06947408 ↗ |
| Route | Subcutaneous | “administered subcutaneously on Day 1” NCT06213844 ↗ |